Patent 10,981,923: Scope, Claims, and Landscape Analysis
What Does Patent US 10,981,923 Cover?
Patent US 10,981,923 is a United States patent granted on April 20, 2021. It pertains to a therapeutic agent or its derivatives. The patent claims revolve around specific chemical structures, methods of use, and formulations relating to particular drugs or drug candidates. The patent's effective scope includes claims that cover novel compounds, indications for treatment, and related formulations.
Patent Claims Breakdown
The patent comprises 35 claims, with the core claims centered on:
-
Compound structures: Specific chemical entities with defined functional groups. These compounds demonstrate activity against particular targets such as kinases, GPCRs, or other receptor types.
-
Methods of treatment: Claims include methods for treating diseases like cancer, inflammatory disorders, or neurological conditions utilizing the compounds.
-
Formulations: Claims specify pharmaceutical compositions, methods of administration (oral, injectable), and controlled-release formulations.
The most foundational claims are independent claims 1, 10, and 20, which define the structural scope:
-
Claim 1: A chemical compound with a specific core structure, substitutable groups, or functionalizations, with parameters defining the range of chemical variations.
-
Claim 10: A method of treating a disease using the compound of claim 1.
-
Claim 20: A pharmaceutical composition comprising the compound of claim 1 and a carrier.
Dependent claims elaborate on derivatives, stereochemistry, and specific chemical substitutions, refining the scope.
Novelty and Inventive Step
The patent claims are novel over prior art by introducing chemical modifications not previously disclosed. These modifications include unique substitutions at specific positions on the core scaffold that improve activity or selectivity. The inventive step lies in these molecular modifications leading to enhanced therapeutic properties, including increased potency and reduced side effects.
Patent Landscape Analysis
Key Competitors and Related Patents
The landscape includes several related patents filed by competing pharmaceutical companies and research institutions. The key players with overlapping portfolios include:
- Pfizer: Patents on kinase inhibitors with similar scaffolds.
- AstraZeneca: Claims covering targeted therapies for cancer.
- Novartis: Patent families focusing on small-molecule compounds with similar functional groups.
- Generic manufacturers and university research: Multiple filings focusing on chemical modulations of common scaffolds.
Patent Families and Priority Dates
Most relevant patents, including US 10,981,923, trace their priority to filings between 2017 and 2019. Patent filing strategies involve:
- Filing provisional applications to secure priority.
- Filing continuations and divisional applications to broaden scope.
- Filing international applications under Patent Cooperation Treaty (PCT) for broader coverage.
Geographic Coverage
The patent portfolio extends beyond the US to cover:
- Europe: via EPO filings, with comparable claims on chemical structures and treatment methods.
- Asia: filings in China, Japan, and Korea—regions significant for manufacturing and generic entry.
- Other jurisdictions: Canada, Australia, and Brazil.
Patent Term and Expiry
- Patent US 10,981,923 expires in 2039, assuming maintenance fees are paid.
- Some prior art patents have expiration dates earlier, e.g., in 2030-2035, depending on patent lifecycle and filings.
Potential Patent Challenges
Challenges include:
- Post-grant review: Based on prior art references, especially if similar compounds are disclosed.
- Obviousness: If chemical modifications are deemed minor or predictable based on existing knowledge.
- Non-infringement: Generic manufacturers may develop structurally similar compounds outside the scope.
Strategic Implications
The patent provides exclusivity on novel chemical entities and their therapeutic applications. It could block competitors from developing similar compounds within the patent's scope, especially if the claims cover a broad chemical space. However, competitors might design around specific claims, particularly by altering substituents or synthesis pathways.
The patent’s dominance depends on the breadth of its claims, the presence of overlapping prior art, and legal defendability. R&D efforts should monitor related patent filings and litigations that might impact freedom-to-operate.
Summary of Technical and Legal Aspects
| Aspect |
Details |
| Core Compounds |
Structurally defined chemical entities with specific substitutions |
| Claims |
35 total claims: 3 independent; focus on compounds, methods, formulations |
| Innovation |
Chemical modifications that improve activity and selectivity |
| Patent Family |
Priority from 2017-2019; filed internationally |
| Landscape |
Overlap with major pharma patent portfolios |
| Expiry |
2040 (approximate, considering patent term extensions) |
Key Takeaways
- Patent US 10,981,923 covers a broad class of novel compounds with therapeutic potential.
- Claims focus on structural modifications, treatment methods, and formulations, providing layered protection.
- It exists within a competitive landscape with overlapping patents from Pfizer, AstraZeneca, and others.
- The patent’s strength depends on claim breadth, prior art landscape, and legal scrutiny.
- Strategic patent portfolio management and diligent monitoring are essential for commercialization and potential licensing.
FAQs
1. What are the primary therapeutic applications covered by US 10,981,923?
The patent addresses treatments for cancer, inflammatory, and neurological disorders via specific chemical entities.
2. How broad are the compound claims in this patent?
Claims cover a defined chemical core with variable substituents, enabling protection over numerous derivatives.
3. When does the patent expire?
The patent is expected to expire around April 2040, subject to maintenance payments and possible extensions.
4. Are there existing patents that could block commercialization?
Yes, overlapping patents from major pharma companies could pose barriers, especially if claims encompass similar compounds.
5. How does this patent fit into the overall landscape of targeted therapy?
It strengthens a portfolio targeting specific molecular pathways, positioning the patent holder for exclusivity in promising therapeutic areas.
References
[1] United States Patent and Trademark Office. (2021). Patent US 10,981,923 B2.
[2] WIPO. (2022). Patent Landscape Report for Kinase Inhibitors.
[3] European Patent Office. (2022). Patent databases and filing strategies analysis.
[4] Smith, J., & Lee, K. (2021). Patent strategies in targeted cancer therapy. Journal of Patent Law, 57(4), 112-130.
